Actively Recruiting
Comparing Reticulocyte Hemoglobin and Transferrin Saturation to Guide Iron Treatment in People on Dialysis
Led by King Chulalongkorn Memorial Hospital · Updated on 2025-04-04
160
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
Sponsors
K
King Chulalongkorn Memorial Hospital
Lead Sponsor
S
Sysmex Asia Pacific
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to find out which method is better for guiding iron treatment in adult patients with end-stage kidney disease (ESKD) on hemodialysis who have anemia. The main questions it aims to answer are: Can using reticulocyte hemoglobin equivalent (RET-He) to guide intravenous (IV) iron treatment be as effective as using transferrin saturation (TSAT)? Does the method used to guide iron treatment affect outcomes such as death, heart problems, hospitalizations, infections, or the need for blood transfusions? Researchers will compare RET-He-guided iron treatment with TSAT-guided iron treatment to see if RET-He works just as well and has similar or better outcomes. Participants will: Receive IV iron based on either RET-He or TSAT levels Have blood tests done at the start, 3 months, and 6 months Have their doses of iron and erythropoietin (a medication to treat anemia) adjusted based on the assigned protocol Be monitored for clinical outcomes such as hospitalization, heart events, and infections
CONDITIONS
Official Title
Comparing Reticulocyte Hemoglobin and Transferrin Saturation to Guide Iron Treatment in People on Dialysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult aged 18 to 80 years
- End-stage kidney disease on chronic hemodialysis for at least 6 months
- Receiving erythropoietin therapy for at least 6 months
- Hemoglobin less than 13.0 g/dL for males or less than 12.0 g/dL for females
You will not qualify if you...
- Serum ferritin greater than 800 ng/mL or transferrin saturation greater than 40%
- Active infection or malignancy
- Hematologic diseases such as thalassemia major, hemolysis, myelofibrosis, or myelodysplastic disease
- Use of marrow suppressive or immunosuppressive medications within the past 6 months
- History of active heart failure or recent myocardial infarction or stroke within the past 6 months
- History of gastrointestinal or external bleeding or blood transfusion within the past 6 months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
King Chulalongkorn Memorial Hospital
Pathumwan, Bangkok, Thailand, 10330
Actively Recruiting
Research Team
J
Jeerath Jeerath Phannajit M.D.
CONTACT
C
Chalermchon Suttaluang M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here